EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bispecific BAFF-R/BCMA CAR T cells control growth of heterogeneous plasma cells in multiple myeloma

Agnese Fiori, Karin Zimmermann, Anna Li, Jörg Westermann, Ioannis Anagnostopoulos, Lutz Menzel, Mario Bunse, Henry Erdlei, Jeyan Jayarajan, Florian Grünschläger, Juan Pablo Ortiz-Aguirre, Simon Haas und 13 weitere

Molecular Therapy · 2026

DOI: 10.1016/j.ymthe.2025.12.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2026. Verfasst von Agnese Fiori und 24 weiteren Autor:innen. Beteiligte Einrichtung: Max-Delbrück-Center for Molecular Medicine, Department of Translational Tumorimmunology, 13125 Berlin, Germany. Hauptthemen laut MEDLINE: Multiple Myeloma, B-Cell Maturation Antigen, Plasma Cells, B-Cell Activation Factor Receptor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020 Framework Programme, H2020 Marie Skłodowska-Curie Actions.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma treatment has experienced tremendous advances through chimeric antigen receptor (CAR) therapies directed to the B cell maturation antigen (BCMA), but remissions are usually transient. To mitigate the risk of BCMA immune escape, we aimed for a simultaneous targeting of BCMA together with the B cell-activating factor receptor (BAFF-R). Single-cell RNA sequencing discovered increased BAFF-R gene (TNFRSF13C) expression in relapsed and refractory multiple myeloma cases, and it emerged as prognostic marker for long-term complete responses. BAFF-R was expressed in plasma cells at earlier maturation stages compared with BCMA-positive plasma cell phenotypes. Bispecific BAFF-R/BCMA CARs endowed T cells with cytolytic efficacy against multiple myeloma cell lines and primary multiple myeloma cells. In vivo, the dual CAR compensated for BCMA downregulation when BAFF-R was expressed, preventing the evolution of antigen escape mutants that drive resistance to CAR T cell therapy. Our study proposes BAFF-R as a complementary target antigen suitable to eliminate malignant plasma cells with less advanced differentiation, lack of BCMA, and occurrence in dismal prognosis patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaB-Cell Maturation AntigenPlasma CellsB-Cell Activation Factor ReceptorImmunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesHumansCell Line, TumorAnimalsMiceXenograft Model Antitumor Assays

Stichwörter der Autor:innen

B cell maturation antigenB cell-activating factor receptorT cellsantigen escapechimeric antigen receptorimmune escapeimmunotherapymultiple myelomaplasma cell

Substanzen

B-Cell Maturation AntigenB-Cell Activation Factor ReceptorReceptors, Chimeric AntigenTNFRSF13C protein, human

Autor:innen und Institutionen

  • Max-Delbrück-Center for Molecular Medicine, Department of Translational Tumorimmunology, 13125 Berlin, Germany.
  • Max-Delbrück-Center for Molecular Medicine, Department of Microenvironmental Regulation in Autoimmunity and Cancer, 13125 Berlin, Germany.
  • Charité-University Medicine Berlin, Department of Hematology, Oncology and Tumorimmunology, Campus Virchow Klinikum, 13353 Berlin, Germany.
  • University of Würzburg, Institute of Pathology, 97080 Würzburg, Germany.
  • Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), 69120 Heidelberg, Germany; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
  • Max-Delbrück-Center for Molecular Medicine, Department of Translational Tumorimmunology, 13125 Berlin, Germany; Charité-University Medicine Berlin, Department of Hematology, Oncology and Tumorimmunology, Campus Virchow…

Förderung

  • Horizon 2020 Framework Programme
  • H2020 Marie Skłodowska-Curie Actions

Zitieren

APA

Fiori, A., Zimmermann, K., Li, A., Westermann, J., Anagnostopoulos, I., Menzel, L., Bunse, M., Erdlei, H., Jayarajan, J., Grünschläger, F., Ortiz-Aguirre, J. P., Haas, S., Teßmann, U. J., Freitag, J., Rosenwald, A., Kwak, L., Wang, X., Dong, Z., Cha, S., …, & Rehm, A. (2026). Bispecific BAFF-R/BCMA CAR T cells control growth of heterogeneous plasma cells in multiple myeloma. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2025.12.005

Vancouver

Fiori A, Zimmermann K, Li A, Westermann J, Anagnostopoulos I, Menzel L, et al. Bispecific BAFF-R/BCMA CAR T cells control growth of heterogeneous plasma cells in multiple myeloma. Molecular Therapy. 2026. doi:10.1016/j.ymthe.2025.12.005

BibTeX
@article{Fiori2026,
  author = {Fiori, Agnese and Zimmermann, Karin and Li, Anna and Westermann, Jörg and Anagnostopoulos, Ioannis and Menzel, Lutz and Bunse, Mario and Erdlei, Henry and Jayarajan, Jeyan and Grünschläger, Florian and Ortiz-Aguirre, Juan Pablo and Haas, Simon and Teßmann, Uwe-Jens and Freitag, Jens and Rosenwald, Andreas and Kwak, Larry and Wang, Xiuli and Dong, Zhenyuan and Cha, Soungchul and Reiser, John and Peralta, Eigen and Valamehr, Bahram and Krönke, Jan and Höpken, Uta E and Rehm, Armin},
  title = {Bispecific BAFF-R/BCMA CAR T cells control growth of heterogeneous plasma cells in multiple myeloma},
  journal = {Molecular Therapy},
  year = {2026},
  doi = {10.1016/j.ymthe.2025.12.005}
}
Kostenlos starten →